549520-67-4Relevant articles and documents
Cancer chemotherapy: A SN-38 (7-Ethyl-10-hydroxycamptothecin) glucuronide prodrug for treatment by a PMT (Prodrug monoTherapy) strategy
Angenault, Stephane,Thirot, Sylvie,Schmidt, Frederic,Monneret, Claude,Pfeiffer, Bruno,Renard, Pierre
, p. 947 - 950 (2003)
A glucuronide-based prodrug of SN-38 (7-ethyl-10-hydroxycamptothecin) has been synthesized for use in a Prodrug MonoTherapy Strategy (PMT). Since this prodrug is significantly less cytotoxic than SN-38 itself and efficiently releases the drug in vitro in the presence of β-D-glucuronidase, it can be considered as an appropriate candidate for cancer treatment by a PMT strategy.